Jeff Davis, a partner in the Washington, D.C., law office of Bass, Berry & Sims, advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the ...

The Health Resources and Services Administration (HRSA) issued a notice announcing the application process for the 340B rebate model pilot program and requesting public comment. The notice sets the ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare ...

While a federal judge squashed earlier plans for a 340B rebate pilot program, HHS appears poised to relaunch its attempts to transform the drug pricing program. Less than two weeks after the federal ...

On October 30, HRSA announced that it had selected eight drug manufacturers to participate in its 340B Rebate Model Pilot Program, spanning 10 drugs representing a range of widely used therapies.

HHS in a court filing on Thursday said it would scrap its current 340B Rebate Model Pilot Program and potentially restart the administrative process for such a program. These moves come after the 1st ...

The hospital lobby is asking federal officials to head off expanded data collection policies some drugmakers are implementing for providers participating in the 340B drug discount program.

In July, the Health Resources and Services Administration announced the availability of a voluntary 340B Rebate Model Pilot Program. The program is voluntary for drugmakers, but not for hospitals, ...

The American Hospital Association sharply criticized a 340B rebate model pilot program from the Health Resources and Services Administration, an agency of HSS, warning the model threatens to undermine ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation and ...

The federal agency overseeing the controversial 340B Rebate Model Pilot Program has “vastly underestimated” how much time and money hospitals obligated to participate will spend on reporting burdens, ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...